Skip to main content
FDA accepts Sandoz's application for biosimilar rituximab
9/12/2017

The FDA will review an application from Novartis unit Sandoz for rituximab, a biosimilar version of Roche's Rituxan for hematological cancers, rheumatoid arthritis and other immunological diseases, according to a Novartis announcement.

Full Story: